TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Sai Life Sciences Ltd.

SAILIFE on NSE · 19 Nov 2026

NIFTY 500

1,788.40 ▲ +0.02 % on the day

Overview Technical Risk & rank Results Accounts Filings Guidance & governance

Filings

31 filings of SAILIFE since February 2025.

board outcome 9, presentation 9, transcript 8, credit rating 3, results 2

FiledTypeSubject
13 Nov 2026credit rating
Capex, Rating
Sai Life Sciences Limited has informed the Exchange about Credit Rating- Revision
AI summary

Sai Life Sciences filed a credit rating update under Regulation 30: India Ratings & Research upgraded its long-term bank loan facilities rating to IND AA (Stable) from IND AA- (Positive) on 13 November 2026, for rated limits of INR 7,690 million.

The short-term rating was affirmed at IND A1+.

India Ratings cites expected sustained improvement in the business and financial profile, stronger operating profitability and comfortable credit metrics.

The agency notes planned FY27 capex of INR 11-13 billion, which is expected to raise net leverage above current low levels; a negative rating action could follow if net leverage exceeds 1.5x on a sustained basis.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Nov 2026transcript
Capex, Guidance, Results
Sai Life Sciences Limited has informed the Exchange about Transcript
AI summary

Sai Life Sciences filed the transcript of its Q2 FY27 earnings conference call held on 6 November 2026, following its unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026.

Management said Q2 FY27 revenue grew 23% year-on-year (CDMO up 20%, CRO up 28%), and H1 FY27 revenue grew 17%; EBITDA margin was 28% for the quarter and for the half year.

Management said capex of about INR621 crores was incurred in H1 FY27 (INR358 crores in Q2), and the FY27 capex plan of INR1,100-1,300 crores remains on track.

The Bidar expansion of about 220 KL is ready and in final quality trials; the further 225 KL phase is now expected by early Q3 FY28 versus earlier timelines, and a new Telangana site is expected to break ground in Q4 FY27.

Management cited higher solvent and chemical costs from the Middle East situation, which it is seeking to recover from customers, and said it cannot give guidance on CRO headcount growth.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2026presentation
Capex, Guidance, Results
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
AI summary

Sai Life Sciences filed the investor presentation for its unaudited standalone and consolidated results for Q2 and H1 FY27 (quarter and half year ended 30 September 2026), to be used at an earnings call on 6 November 2026 at 11:00 AM IST.

Q2 FY27: revenue ₹659 Cr (up 23% YoY), material margin ₹484 Cr (up 22% YoY), EBITDA ₹187 Cr (up 20% YoY), PAT ₹98 Cr (up 17% YoY); CDMO 64% and CRO 36% of revenue mix; capacity utilization 67%.

H1 FY27: revenue ₹1,213 Cr (up 17% YoY), material margin ₹893 Cr (up 19% YoY), EBITDA ₹335 Cr (up 19% YoY), PAT ₹172 Cr (up 19% YoY); capex incurred ₹621 Cr.

Management (Krishna Kanumuri, MD & CEO) said Q2 FY27 was a strong quarter, with growing traction with global pharma companies and customer engagements evolving into larger, strategic relationships.

Management (Siva Chittor, Whole-time Director & CFO) said EBITDA margin was 28%, that they continue to expect a stronger second half, and that the capacity expansion programme remains on track.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Nov 2026board outcome
Dividend / buy-back, Management change, Results
Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Sai Life Sciences Limited filed the outcome of its board meeting held on 05 November 2026.

The board approved the unaudited standalone and consolidated financial results for the second quarter and half year ended 30 September 2026, with limited review reports enclosed.

The board appointed Mr. Sidhartha Das as Senior Vice President & Head - Human Resources, Mr. Vijay Kumar Suthari as Vice President - Head Quality & Regulatory Affairs, and Mr. Sriram Gopalakrishnan as Senior Vice President - Corporate Communications, all as Senior Management Personnel with effect from 05 November 2026.

The company allotted 27,005 and 81,000 equity shares of face value ₹1 each on exercise of options under ESOP 2008 and MESOP 2018; paid-up equity share capital increased from ₹21,24,72,716 to ₹21,25,80,721.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Aug 2026transcript
Capex, Guidance, Results
Sai Life Sciences Limited has informed the Exchange about Transcript
AI summary

Sai Life Sciences filed the transcript of its Q1 FY27 earnings conference call held on 7 August 2026, following its unaudited results for the quarter ended 30 June 2026.

Management said Q1 revenue was INR553 crores, up about 12% year-on-year from INR496 crores, with CRO revenue up about 26% and CDMO revenue up about 6%; CDMO was about 60% of revenue and CRO about 40%.

Management expects a stronger H2 FY27 as planned capacity expansion goes live in the second half of the year.

Management reiterated its longer-term revenue growth guidance of 15% to 20% and EBITDA range of 28% to 30%.

Management said returning customers accounted for over 90% of revenue in FY25 and FY26, and 33 active commercial molecules and 14 late-phase molecules are in the CMC business.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Aug 2026presentation
Capex, Guidance, Results
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
AI summary

Sai Life Sciences filed its investor presentation for the quarter ended 30 June 2026 (Q1FY27).

Q1FY27 revenue was ₹554 crore, up 12% year-on-year; material margin ₹409 crore (up 15%); EBITDA ₹148 crore (up 18%); PAT ₹73 crore (up 22%). Capex incurred was ₹263 crore; capacity utilization 65%.

CRO business grew 24% year-on-year; CDMO/CRO revenue mix was 60%/40%. The company has 33 active commercial molecules and 14 late-phase molecules in its CMC pipeline.

Management (MD & CEO Krishna Kanumuri, CFO Siva Chittor) said it remains confident in long-term revenue growth guidance of 15-20% and EBITDA range of 28-30%, and that over 90% pipeline visibility on FY27 targets exists.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2026board outcome
Results
Sai Life Sciences Limited has submitted to the Exchange, the unaudited financial results (Standalone and Consolidated) for the period ended Jun 30, 2026.
AI summary

Board of Sai Life Sciences Limited approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 at a meeting held on 6 August 2026, and noted the limited review report of Deloitte Haskins & Sells LLP.

Standalone revenue from operations for Q1 FY27 was Rs. 5,467.29 million, against Rs. 4,830.38 million in the year-ago quarter and Rs. 5,943.40 million in the previous quarter.

Standalone profit for the period was Rs. 713.39 million, against Rs. 583.70 million a year earlier; basic EPS was Rs. 3.36 (not annualised).

The statutory auditors issued an unmodified conclusion on the limited review of the quarter's results.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 May 2026transcriptSai Life Sciences Limited has informed the Exchange about Transcript of Earnings Call for the Audited Financial Results of the Company for the quarter and year ended 31 March 2026.
AI summary

Sai Life Sciences Limited filed the transcript of its earnings call held on 15 May 2026 at 4:00 PM IST on the audited financial results for the quarter and year ended 31 March 2026.

The filing is a cover letter under Regulation 30 of SEBI (LODR) Regulations, 2015; the transcript itself is hosted on the company website and is not included in the pages provided.

The pages provided contain no financial figures, management commentary or outlook.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 May 2026presentation
Capex, Guidance, Results
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
AI summary

Sai Life Sciences filed its investor presentation for the quarter and year ended 31 March 2026.

Management (MD & CEO Krishna Kanumuri) said FY26 was an important year, with deeper relationships with global pharma customers and expanded integrated CRDMO capabilities, and that long-term outsourcing fundamentals remain strong while the operating environment is dynamic.

CFO Siva Chittor said FY26 showed strong execution with healthy growth in revenues and EBITDA.

FY26 capex was ₹633 crore against a budget of ₹700 crore; FY27 capex is planned at ₹1,100–1,300 crore, mainly for capacity expansion (about 70%).

Management highlighted commercial supply qualification from two additional large pharma customers and 100% renewable power at its Bidar manufacturing sites (Unit IV and Unit VI).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 May 2026board outcome
Results
Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Sai Life Sciences Limited's board, at its meeting on 14 May 2026, approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, and noted the statutory auditor's report (Deloitte Haskins & Sells LLP).

Standalone revenue from operations for FY2026 was Rs 21,532.26 million, up from Rs 16,420.48 million in FY2025; Q4 FY2026 revenue was Rs 5,943.40 million.

Standalone profit for the year was Rs 3,414.81 million (FY2025: Rs 1,734.62 million); Q4 FY2026 profit was Rs 1,025.32 million.

Standalone basic EPS for FY2026 was Rs 16.27 annualised (FY2025: Rs 9.00).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 Feb 2026credit rating
Rating
Sai Life Sciences Limited has informed the Exchange about Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015 - ICRA Limited issued its ratings of the Company.
AI summary

Sai Life Sciences Limited filed an intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015, enclosing a credit rating letter from ICRA Limited dated 26 February 2026.

ICRA assigned [ICRA]AA (Stable) to long-term fund-based (others) facilities of Rs. 550.00 crore and [ICRA]A1+ (Stable) to short-term non-fund-based (others) facilities of Rs. 218.60 crore, a total rated amount of Rs. 768.60 crore.

The ratings will be due for surveillance within one year from the date of the rating communication letter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2026transcript
Results
Sai Life Sciences Limited has informed the Exchange about Transcript for the Un-audited Financial Results for the quarter and nine months ended on 3 December 2025.
AI summary

Sai Life Sciences filed the transcript of its earnings call held on 6 February 2026 for the unaudited results for the quarter and nine months ended 31 December 2025.

The filing itself gives no financial figures; the transcript is available on the company website.

The covering letter is signed by Runa Karan, Company Secretary & Compliance Officer.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Feb 2026presentation
Capex, Guidance, Results
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
AI summary

Sai Life Sciences filed its investor presentation for Q3 and nine months ended 31 December 2025.

Q3FY26 total revenue was ₹556 Cr, up 27% year-on-year from ₹440 Cr; EBITDA was ₹191 Cr, up 54% from ₹124 Cr, with margin up 605 bps to 34%; PAT was ₹100 Cr, up 86% from ₹54 Cr.

CDMO revenue was ₹361 Cr (up 31% from ₹276 Cr) and CRO revenue was ₹195 Cr (up 19% from ₹164 Cr).

Management said capex of ₹405 Cr has been invested as on date against a FY26 plan of ₹700 Cr, and that the company remains confident in sustaining growth momentum in the coming year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Feb 2026board outcome
Results
Sai Life Sciences Limited has submitted to the Exchange, the unaudited financial results (Standalone and Consolidated) for the period ended December 31, 2025.
AI summary

Sai Life Sciences' board on 05 February 2026 approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025; the statutory auditor's limited review report (Deloitte Haskins & Sells LLP) was noted.

Standalone revenue from operations was Rs. 5,491.79 million for the quarter ended 31 December 2025 (Rs. 4,286.02 million a year earlier) and Rs. 15,588.86 million for the nine months.

Standalone net profit for the quarter was Rs. 976.30 million (Rs. 510.57 million a year earlier), and Rs. 2,389.49 million for the nine months.

An exceptional loss of Rs. 82.93 million arose from increased gratuity and leave liabilities following the Labour Codes notified on 21 November 2025.

Standalone basic EPS for the quarter was Rs. 4.64 (not annualised).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Nov 2025transcriptSai Life Sciences Limited has informed the Exchange about Transcript
AI summary

Sai Life Sciences Limited filed the transcript of its earnings call held on 7 November 2025 at 4:00 PM IST on the unaudited financial results for the quarter and half year ended 30 September 2025.

The filing is a cover letter under Regulation 30 of SEBI (LODR) Regulations, 2015; the transcript itself is hosted on the company website and is not included in the pages provided.

The pages provided do not contain management's remarks on results, guidance or business performance.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Nov 2025presentation
Capex, Results
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
AI summary

Sai Life Sciences filed its investor presentation for the quarter and half year ended 30 September 2025.

Q2FY26 total revenue was ₹537 Cr, up 36% year-on-year from ₹396 Cr; CDMO revenue was ₹352 Cr (up 37%) and CRO revenue was ₹185 Cr (up 19%).

Q2FY26 EBITDA was ₹156 Cr (29.0% margin) versus ₹109 Cr (27.5%) in Q2FY25; PAT was ₹84 Cr versus ₹42 Cr a year earlier.

Management (CFO Siva Chittor) said capex of ₹248 Cr was incurred in H1, primarily for R&D capacity and new modalities and technologies.

Management (MD & CEO Krishna Kanumuri) described the quarter as another strong one, with healthy demand and continued investment in capacity expansion.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2025board outcome
Results
Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Board of Sai Life Sciences Limited approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025 on 06 November 2025 (meeting 6:00 PM to 7:13 PM IST); Deloitte Haskins & Sells LLP limited review report noted.

Standalone revenue from operations was Rs 5,266.69 million for the quarter ended 30 September 2025, up from Rs 4,830.38 million in the quarter ended 30 June 2025 and Rs 3,819.71 million in the quarter ended 30 September 2024.

Standalone profit for the period was Rs 829.49 million for the quarter ended 30 September 2025, versus Rs 583.70 million in the June 2025 quarter and Rs 438.49 million in the September 2024 quarter.

For the six months ended 30 September 2025, standalone revenue from operations was Rs 10,097.07 million and profit was Rs 1,413.19 million, compared with Rs 6,464.40 million and Rs 324.70 million in the six months ended 30 September 2024.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Aug 2025transcriptTranscript of Earnings Call for the Un-audited Financial Results of the Company for the quarter ended June 30, 2025.
AI summary

Sai Life Sciences filed the transcript of its earnings call held on 8 August 2025 at 4:00 PM IST, discussing unaudited financial results for the quarter ended June 30, 2025.

The filing is a cover letter under Regulation 30 of SEBI (LODR) Regulations, 2015; the transcript itself is hosted on the company website and is not included in the pages provided.

The pages provided do not contain management's remarks, financial figures, or outlook.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Aug 2025credit rating
Capex, Rating
Sai Life Sciences Limited has informed the Exchange about Credit Rating- Revision
AI summary

Sai Life Sciences filed under Regulation 30 to intimate that India Ratings & Research (Fitch Group) upgraded its ratings of the company on 14 August 2025.

Bank loan facility of INR 7,690 million (reduced from INR 11,800 million) rated IND AA-/Positive/IND A1+, upgraded from IND A+/Stable/IND A1+; short-term rating affirmed.

Ind-Ra cites FY25 consolidated revenue up 16% yoy to INR 16,946 million, EBITDA of INR 4,057 million and EBITDA margin of 23.9%, and net leverage of nil in FY25.

Ind-Ra notes the Positive Outlook reflects expected substantial improvement in financial performance over the near-to-medium term, and that net leverage is expected to stay below 1.5x despite planned capex of INR 7 billion over FY26-FY27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
08 Aug 2025presentation
Capex, Results
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
AI summary

Sai Life Sciences filed its investor presentation for the quarter ended 30 June 2025 (Q1FY26), dated 08 August 2025.

Consolidated revenue for Q1FY26 was ₹496 Cr, up 77% from ₹280 Cr in Q1FY25; CDMO revenue was ₹314 Cr (up 113% from ₹148 Cr) and CRO revenue was ₹182 Cr (up 38% from ₹132 Cr).

EBITDA was ₹125 Cr versus ₹31 Cr in Q1FY25, with EBITDA margin at 25% (11% in Q1FY25); PAT was ₹60 Cr versus ₹12 Cr-equivalent loss-to-profit comparison of -₹13 Cr in Q1FY25 margin figures as printed.

Capital expenditure during Q1FY26 was ₹134 Cr.

The CFO said the company is optimistic about its growth trajectory, and the CEO described a strong start to FY26 with new Biology labs inaugurated and a new Process R&D block broken ground at Hyderabad.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Aug 2025board outcome
Management change, Results
Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Board of Sai Life Sciences approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2025, with a limited review report from Deloitte Haskins & Sells LLP (unmodified conclusion).

Standalone revenue from operations for Q1 FY26 was Rs 4,830.38 million, against Rs 2,644.69 million in the quarter ended 30 June 2024; standalone net profit was Rs 583.70 million, against a loss of Rs 113.79 million a year earlier.

Board approved reappointment of Mr. Krishnamraju Kanumuri as Managing Director & CEO for 5 years effective 01 September 2025, subject to member approval at the AGM.

The 26th Annual General Meeting is scheduled for 11 September 2025 at 04:00 PM (IST) via video conferencing or other audio-visual means.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 May 2025transcript
Capex, Guidance, Results
Sai Life Sciences Limited has informed the Exchange about Transcript
AI summary

Sai Life Sciences filed the transcript of its Q4 and FY25 earnings call, held on 14 May 2025, under Regulation 30 of SEBI LODR.

Management said FY25 revenue from operations was around INR1,695 crores, up 16% from INR1,465 crores in FY24, with EBITDA of INR425 crores (25% margin, up from 20%) and PAT of INR170 crores versus INR83 crores.

Management said a one-time provision of around INR34 crores for bad debt and contract assets, linked to customer de-stocking, was taken in Q4 within other expenses.

Management said FY25 capex was INR408 crores and that FY26 capex is expected to be close to INR700 crores, to be funded from internal accruals, debt and IPO proceeds.

Management said capacity utilisation was 67% in FY25 and that a new capacity addition is coming online in May 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 May 2025presentation
Capex, Results
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
AI summary

Sai Life Sciences filed its investor presentation for the year ended 31 March 2025 (FY25), dated 14 May 2025.

Management (MD & CEO Krishna Kanumuri) said FY25 showed a strong performance, with revenue up 16%, EBITDA margin expanded to 25%, and profit after tax up 105%, supported by lower finance costs and operating leverage.

Management (CFO Siva Chittor) said the company completed a planned ₹720 Cr debt repayment and expects lower interest costs from FY26; FY25 capex was ₹408 Cr.

Presentation figures show FY25 revenue of ₹1,695 Cr, material margin of ₹1,229 Cr (73%), EBITDA of ₹425 Cr and PAT of ₹170 Cr (10%).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 May 2025board outcome
Results
Sai Life Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2025.
AI summary

Sai Life Sciences filed the outcome of its 13 May 2025 board meeting, which approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2025.

The board noted the audit report of statutory auditors Deloitte Haskins & Sells LLP on the results.

The board meeting commenced at 6:30 PM (IST) and concluded at 10:30 PM (IST).

The filing states the results are enclosed as an Annexure; the pages provided do not show the revenue, profit or other figures.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 May 2025board outcome
Results
Sai Life Sciences Limited has informed the Exchange regarding Board meeting held on May 13, 2025.
AI summary

Sai Life Sciences filed the outcome of its board meeting held on 13 May 2025 under Regulations 30 and 33 of the SEBI Listing Regulations.

The board approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, noting the audit report of statutory auditors Deloitte Haskins & Sells LLP.

The board meeting commenced at 6:30 PM (IST) and concluded at 10:30 PM (IST).

The pages provided do not include the revenue, profit or dividend figures.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Feb 2025presentation
Capex, Dividend / buy-back, Guidance, Results
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
AI summary

Sai Life Sciences filed an updated investor presentation for the quarter ended 31 December 2024 (Q3 FY25), adding a revenue split between CRO and CDMO activities at the request of investors.

Q3 FY25 revenue from operations was ₹439.8 Cr, up 15% from ₹383.6 Cr in Q3 FY24; EBITDA was ₹124 Cr with a margin of 28.3%; PAT was ₹53.9 Cr versus ₹39.6 Cr.

9MFY25 revenue was ₹1,115 Cr (up 9% YoY), EBITDA ₹264 Cr (up 50% YoY) and PAT ₹82 Cr (up 207% YoY).

Management (MD & CEO Krishna Kanumuri) said the company expects sustained growth momentum supported by a strong order pipeline; capex for 9MFY25 was about ₹300 Cr, and 9MFY25 operating cash flow was ₹246 Cr.

Management said the remaining IPO-linked debt was repaid in January 2025 and expects lower interest costs in the following quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Feb 2025transcript
Capex, Dividend / buy-back, Guidance, Results
Sai Life Sciences Limited has informed the Exchange about Transcript
AI summary

Sai Life Sciences filed the transcript of its Q3 FY25 earnings conference call, held on 07 February 2025, on the unaudited results for the quarter and nine months ended 31 December 2024.

Management (CEO Krishna Kanumuri, CFO Siva Chittor) said Q3 revenue from operations rose 15% year-on-year to 440 crores, with EBITDA margin at 28% and PAT up 36% to 54 crores.

For the nine months, total income rose 9% to 1,142 crores, EBITDA margin was 24% versus 17%, and PAT was 82 crores versus 27 crores.

Management said it does not give specific guidance on parameters, but aspires to a revenue CAGR of 15-20% over 3-5 year blocks and an EBITDA margin of 28-30%.

Capital expenditure for the nine months was 300 crores, and the company added 100 KL of manufacturing capacity in November 2024 with another 100 KL expected in Q1 FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Feb 2025presentation
Capex, Guidance, Results
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
AI summary

Sai Life Sciences filed its investor update presentation for the quarter ended 31 December 2024 (Q3 FY25).

Q3 FY25 revenue from operations was ₹439.8 Cr, up 15% from ₹383.6 Cr in Q3 FY24; EBITDA was ₹124 Cr (28.3% margin) and PAT was ₹53.9 Cr, up from ₹39.6 Cr.

For 9MFY25, revenue was ₹1,115 Cr (up 9% YoY), EBITDA ₹264 Cr (up 50% YoY) and PAT ₹82 Cr (up 207% YoY).

Management said capital expenditure for 9MFY25 was about ₹300 Cr and that ₹585.7 Cr of IPO-linked debt had been repaid by December 2024, with the remaining balance repaid in January 2025.

Management expects sustained growth momentum, supported by a strong order pipeline and ongoing infrastructure investments.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Feb 2025results
Results
Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024
AI summary

Sai Life Sciences Limited filed its Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024, dated 06 February 2025, under SEBI circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185.

The pages include Deloitte Haskins & Sells LLP's review reports on the standalone and consolidated unaudited interim financial results, with unmodified conclusions.

The consolidated results cover Sai Life Pharma Private Limited, Sai Life Sciences Inc and Sai Life Sciences GMBH.

Deloitte reports that two subsidiaries (reviewed by other auditors) contributed revenues of Rs 312.18 million for the quarter and Rs 900.37 million for nine months ended December 31, 2024.

The financial figures themselves (revenue, profit, EPS) are not in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Feb 2025results
Results
Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Sai Life Sciences Limited filed the outcome of its board meeting held on 06 February 2025, at which the board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024.

The board noted the limited review reports of statutory auditors Deloitte Haskins & Sells LLP, which state that nothing has come to their attention that the results contain material misstatement.

The auditor's reports note that financial information for the quarter ended 30 September 2024 and the corresponding 2023 periods was furnished by management and not audited or reviewed.

The consolidated review report notes that two subsidiaries were reviewed by other auditors, with total revenues of Rs 312.18 million for the quarter and Rs 900.37 million for the nine months ended 31 December 2024.

The board meeting ran from 6.30 PM to 9.15 PM (IST).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Feb 2025board outcome
Results
Sai Life Sciences Limited has informed the Exchange regarding Board meeting held on February 06, 2025.
AI summary

Sai Life Sciences Limited filed the outcome of its board meeting held on 06 February 2025.

The board approved the un-audited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024.

Statutory auditors M/s. Deloitte Haskins & Sells LLP issued limited review reports on both sets of results, with no modifications to their conclusions.

The board meeting ran from 6.30 PM to 9.15 PM (IST).

The pages provided do not state the revenue, profit or dividend figures.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in